TAK-360

Drug

Related News

Takeda Advances Two Neuroscience Clinical Trials: Narcolepsy and Teen Depression

Jun 11, 2026

Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.

FDA Grants Priority Review to Takeda's Oveporexton for Narcolepsy Type 1

May 03, 2025

The FDA accepted Takeda's NDA for oveporexton (TAK-861), an oral orexin receptor 2 agonist for narcolepsy type 1, and granted Priority Review with a PDUFA goal date in Q3 2026. The drug could become the first approved orexin agonist.